"Cancer-related cachexia and sarcopenia occur in hematologic malignancies, not just gastrointestinal carcinomas and head and neck cancers. Their presence affects all aspects of diagnosis and treatment ...
Muscle atrophy is a primary characteristic of both sarcopenia and cachexia, significantly impacting physical function and quality of life. This figure illustrates the multifaceted causes of muscle ...
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual ...
It is hoped that the findings from a Nottingham Trent University study could be used to help delay the impact of the aging process. The study, which also involved Sweden's Karolinska Institute, ...
Sarcopenia prevalence in gynecologic cancer patients ranges from 9.5% to 62.7%, with a pooled prevalence of 38.8%. Higher sarcopenia rates are observed in patients over 60 and those with a BMI over 25 ...
MUNICH--(BUSINESS WIRE)--CatalYm today announced new findings from its ongoing Phase 1/2a study as well as preclinical research, highlighting the therapeutic potential of its lead drug candidate, ...
MIAMI, FL, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results